/
Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$9M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$10M
▲ +49.0% YoY
Op. Margin
—
ROIC
-121.62%
▲ +46.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▼ -194.0% YoY
Op. Cash Flow (TTM)
-$8M
▼ -194.0% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$3M
Continue Research